image21
Artistic interpretation of ocular anatomy. Courtesy of Project VISIONS (www.the-visions.com)

Therapeutics for Age-related Macular Degeneration (AMD)

Visgenx is developing therapeutics to protect against the loss of sight  from retinal disorders.  Our programs are based on increasing the expression of a gene which may prevent the loss of retinal cells critical for vision.

THERAPEUTIC FOCUS

Age-related Macular Degeneration / Geographic Atrophy



DEVELOPMENT STRATEGY

Our fast-to-market approach is based on increasing gene expression using the de-methylating agent decitabine.  Our longer term goal is gene therapy.